5月25日，据CDE官网消息，上海岸迈生物科技有限公司联合申请药品“EMB-01注射液”，获得临床试验默示许可，受理号CXSL2500222。
公示信息显示，药品“EMB-01注射液”适应症：复发性转移性结直肠癌。
上海岸迈生物科技有限公司，成立于2016年，位于上海市，是一家以从事医药制造业为主的企业。企业注册资本21000万美元，实缴资本18949.965万美元。
通过天眼查大数据分析，上海岸迈生物科技有限公司共对外投资了2家企业，专利信息10条，此外企业还拥有行政许可21个。
主要股东信息显示，上海岸迈生物科技有限公司由EpimAb Biotherapeutics (HK) Limited持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.